Premium
Circulating Biomarkers in Breast Cancer Prognosis and Survival: A Systematic Review
Author(s) -
Cheng Junrui,
Liu Shanshan,
Zhang Fang Fang
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.906.21
Subject(s) - medicine , breast cancer , oncology , cancer , cause of death , disease , meta analysis
Purpose Previous studies of survivors of breast cancer have drawn heterogeneous conclusions regarding the association between circulating biomarkers and breast cancer prognosis and survival. We sought to determine the role of circulating biomarkers in breast cancer prognosis and survival through the conduct of a systematic review and meta‐analysis. Methods A MEDLINE search was performed from its inception through 2014. Studies met the inclusion criteria if they: (1) included at least 10 women diagnosed with breast cancer of any age, stage, and menopausal status; (2) assessed circulating biomarkers at least one year prior to ascertaining breast cancer prognosis and survival outcomes; (3) evaluated all‐cause mortality, breast cancer death, recurrence, or disease‐free survival. Results Twenty‐six studies met the inclusion criteria for systematic review. Fourteen studies were subject to meta‐analysis that included a total of 11,954 breast cancer survivors. High circulating levels of C‐reactive protein (CRP) were associated with an increased risk of all‐cause mortality (HR = 1.7, 95% CI: 1.1‐2.5), breast cancer death (HR = 1.8, 95% CI: 1.4‐2.4), recurrence (HR = 1.3, 95% CI: 0.9‐1.9), and reduced disease‐free survival (HR = 1.9, 95% CI: 1.3‐2.2). High circulating levels of glucose were associated with an increased risk of all‐cause mortality (HR = 1.9, 95% CI: 1.2‐2.8) and breast cancer recurrence (HR = 1.6, 95% CI: 1.0‐2.6). Existing evidence did not support associations between other circulating biomarkers and breast cancer prognosis and survival. Conclusions Circulating CRP and glucose can serve as valuable biomarkers to predict breast cancer prognosis and survival.